Boldrini Luca, Charles-Davies Diepriye, Romano Angela, Mancino Matteo, Nacci Ilaria, Tran Huong Elena, Bono Francesco, Boccia Edda, Gambacorta Maria Antonietta, Chiloiro Giuditta
UOC Radioterapia Oncologica, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy; Radiomics Core Research Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Radiomics Core Research Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Eur J Surg Oncol. 2024 Nov 15:109463. doi: 10.1016/j.ejso.2024.109463.
Predicting pathological complete response (pCR) from pre or post-treatment features could be significant in improving the process of making clinical decisions and providing a more personalized treatment approach for better treatment outcomes. However, the lack of external validation of predictive models, missing in several published articles, is a major issue that can potentially limit the reliability and applicability of predictive models in clinical settings. Therefore, this systematic review described different externally validated methods of predicting response to neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) patients and how they could improve clinical decision-making.
An extensive search for eligible articles was performed on PubMed, Cochrane, and Scopus between 2018 and 2023, using the keywords: (Response OR outcome) prediction AND (neoadjuvant OR chemoradiotherapy) treatment in 'locally advanced Rectal Cancer'.
(i) Studies including patients diagnosed with LARC (T3/4 and N- or any T and N+) by pre-medical imaging and pathological examination or as stated by the author (ii) Standardized nCRT completed. (iii) Treatment with long or short course radiotherapy. (iv) Studies reporting on the prediction of response to nCRT with pathological complete response (pCR) as the primary outcome. (v) Studies reporting external validation results for response prediction. (vi) Regarding language restrictions, only articles in English were accepted.
(i) We excluded case report studies, conference abstracts, reviews, studies reporting patients with distant metastases at diagnosis. (ii) Studies reporting response prediction with only internally validated approaches.
Three researchers (DC-D, FB, HT) independently reviewed and screened titles and abstracts of all articles retrieved after de-duplication. Possible disagreements were resolved through discussion among the three researchers. If necessary, three other researchers (LB, GC, MG) were consulted to make the final decision. The extraction of data was performed using the CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) template and quality assessment was done using the Prediction model Risk Of Bias Assessment Tool (PROBAST).
A total of 4547 records were identified from the three databases. After excluding 392 duplicate results, 4155 records underwent title and abstract screening. Three thousand and eight hundred articles were excluded after title and abstract screening and 355 articles were retrieved. Out of the 355 retrieved articles, 51 studies were assessed for eligibility. Nineteen reports were then excluded due to lack of reports on external validation, while 4 were excluded due to lack of evaluation of pCR as the primary outcome. Only Twenty-eight articles were eligible and included in this systematic review. In terms of quality assessment, 89 % of the models had low concerns in the participants domain, while 11 % had an unclear rating. 96 % of the models were of low concern in both the predictors and outcome domains. The overall rating showed high applicability potential of the models with 82 % showing low concern, while 18 % were deemed unclear.
Most of the external validated techniques showed promising performances and the potential to be applied in clinical settings, which is a crucial step towards evidence-based medicine. However, more studies focused on the external validations of these models in larger cohorts is necessary to ensure that they can reliably predict outcomes in diverse populations.
根据治疗前或治疗后的特征预测病理完全缓解(pCR)对于改善临床决策过程以及提供更个性化的治疗方法以实现更好的治疗效果可能具有重要意义。然而,几篇已发表文章中缺少预测模型的外部验证,这是一个可能会限制预测模型在临床环境中可靠性和适用性的主要问题。因此,本系统评价描述了在局部晚期直肠癌(LARC)患者中预测新辅助放化疗(nCRT)反应的不同外部验证方法,以及它们如何改善临床决策。
在2018年至2023年期间,使用关键词“(反应或结果)预测”和“(新辅助或放化疗)治疗”在‘局部晚期直肠癌’中,对PubMed、Cochrane和Scopus进行了广泛的合格文章搜索。
(i)研究包括通过医学前影像学和病理检查或作者所述诊断为LARC(T3/4和N-或任何T和N+)的患者;(ii)完成标准化nCRT;(iii)采用长疗程或短疗程放疗;(iv)研究报告以病理完全缓解(pCR)作为主要结局对nCRT反应的预测;(v)研究报告反应预测的外部验证结果;(vi)关于语言限制,仅接受英文文章。
(i)我们排除了病例报告研究、会议摘要、综述、报告诊断时有远处转移患者的研究;(ii)仅报告内部验证方法的反应预测研究。
三位研究人员(DC-D、FB、HT)独立审查并筛选了去重后检索到的所有文章的标题和摘要。可能的分歧通过三位研究人员之间的讨论解决。如有必要,咨询另外三位研究人员(LB、GC、MG)以做出最终决定。使用预测模型系统评价的关键评估和数据提取清单(CHARMS)模板进行数据提取,并使用预测模型偏倚风险评估工具(PROBAST)进行质量评估。
从三个数据库中总共识别出4547条记录。排除392条重复结果后,对4155条记录进行了标题和摘要筛选。标题和摘要筛选后排除了3800篇文章,检索到355篇文章。在检索到的355篇文章中,评估了51项研究的 eligibility。然后,由于缺乏外部验证报告,排除了19份报告,由于缺乏对pCR作为主要结局的评估,排除了4份报告。只有28篇文章符合条件并纳入本系统评价。在质量评估方面,89%的模型在参与者领域关注度较低,而11%的评级不明确。96%的模型在预测因素和结局领域关注度较低。总体评级显示模型具有较高的适用性潜力,82%的模型关注度较低,而18%被认为不明确。
大多数外部验证技术显示出有前景的性能以及在临床环境中应用的潜力,这是迈向循证医学的关键一步。然而,需要更多针对这些模型在更大队列中的外部验证的研究,以确保它们能够可靠地预测不同人群的结局。